20/20 HealthCare Partners

Variantyx Inc. is a biotechnology company based in Framingham, Massachusetts, founded in 2014. The company specializes in diagnostic testing for rare disorders through its whole genome sequencing (WGS) platform, known as Genomic Unity®. This innovative test analyzes a single patient sample to identify and report all major variant types, including small sequence changes, structural variants, mitochondrial variants, and short tandem repeat expansions. By providing a comprehensive approach to genetic testing, Variantyx eliminates the need for traditional, step-wise genetic testing methods. The platform is designed to generate clinical reports that help hospitals and commercial laboratories accurately understand a patient's genetic makeup, leading to improved diagnosis and optimized treatment recommendations for inherited disorders.

Variantyx Inc. is a biotechnology company based in Framingham, Massachusetts, founded in 2014. The company specializes in diagnostic testing for rare disorders through its whole genome sequencing (WGS) platform, known as Genomic Unity®. This innovative test analyzes a single patient sample to identify and report all major variant types, including small sequence changes, structural variants, mitochondrial variants, and short tandem repeat expansions. By providing a comprehensive approach to genetic testing, Variantyx eliminates the need for traditional, step-wise genetic testing methods. The platform is designed to generate clinical reports that help hospitals and commercial laboratories accurately understand a patient's genetic makeup, leading to improved diagnosis and optimized treatment recommendations for inherited disorders.

Variantyx Inc. is a biotechnology company based in Framingham, Massachusetts, founded in 2014. The company specializes in diagnostic testing for rare disorders through its whole genome sequencing (WGS) platform, known as Genomic Unity®. This innovative test analyzes a single patient sample to identify and report all major variant types, including small sequence changes, structural variants, mitochondrial variants, and short tandem repeat expansions. By providing a comprehensive approach to genetic testing, Variantyx eliminates the need for traditional, step-wise genetic testing methods. The platform is designed to generate clinical reports that help hospitals and commercial laboratories accurately understand a patient's genetic makeup, leading to improved diagnosis and optimized treatment recommendations for inherited disorders.

Coagulo Medical Technologies, Inc. is a Massachusetts-based company focused on developing advanced testing systems for coagulation management. The company provides a portable and connected precision-medicine platform that enables healthcare professionals to detect, identify, and quantify the effects of various anticoagulants in whole blood. By utilizing a combination of patent-pending coagulation assays, microfluidic technology, and data analytics, Coagulo's system offers actionable results, facilitating personalized diagnosis and management of coagulation-related conditions. This innovative approach aims to improve healthcare outcomes by making coagulation testing more accessible and efficient for both providers and patients.

XRHealth Ltd. is a medical technology company based in Tel Aviv, Israel, that specializes in developing virtual reality (VR) software solutions for healthcare. Founded in 2016, the company offers an array of products designed to enhance patient care and treatment outcomes. Its offerings include VRPhysio, a platform for virtual physical therapy; VRReliever, which helps manage pain through distraction; VRCogni, aimed at improving motor function in stroke and dementia patients; and VRPsyc, which provides exposure therapy for various mental health disorders. Additionally, VRCoordi is designed to aid coordination recovery in patients with Parkinson's, brain injuries, and autism. By integrating immersive technologies with licensed clinicians and advanced data analytics, XRHealth provides comprehensive telehealth services, allowing patients to access treatment from the comfort of their own homes.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Verseau Therapeutics, Inc. is focused on developing macrophage checkpoint modulators aimed at treating patients with cancer, as well as immune and inflammatory diseases. Founded in 2017 and based in Lexington, Massachusetts, the company is creating a new class of therapeutics that target macrophages, which are crucial cells in the immune system. By shifting these cells between immune activators and silencers, Verseau's therapies aim to enhance the body's ability to mount an effective immune response against tumors. This innovative approach seeks to improve the efficacy of existing immunotherapies, offering new hope for patients facing challenging health conditions.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

EightSpokes, Inc. is a company based in Lexington, Massachusetts, that provides a cloud-based software platform designed to enhance program and portfolio management in the life sciences sector. Established in 2012, EightSpokes specializes in launch management through its Enlighten software, which streamlines planning, coordination, and communication processes to mitigate launch delays. The platform facilitates collaboration among various internal teams and external partners, supporting activities from preclinical development to drug commercialization. By improving workflow and synchronizing execution, the software enables clients to reduce costs and accelerate the market introduction of new medicines while effectively managing their product lifecycles and navigating mergers and acquisitions.

PhysIQ, Inc. is a health technology company based in Chicago, Illinois, that specializes in a cloud-based predictive platform for personalized physiology analytics. The company has developed a platform that analyzes multiple data streams to establish individual baseline norms for patients, allowing clinicians to monitor vital signs and detect clinically significant changes. This innovative approach helps manage chronic illnesses by predicting acute medical events before symptoms arise and empowers consumers to take control of their health and fitness. PhysIQ's solution is applicable in both regulated healthcare and unregulated health and fitness markets, and it can be integrated into other patient monitoring devices, enhancing their capabilities. Founded in 2013, PhysIQ was previously known as VGBio, Inc.

A solar panel that tracks the sun throughout the day produces up to 30% more electricity than one that does not. Solar project developers install single-axis tracking for most utility-scale sites, balancing upfront costs versus electricity revenues to maximize rates of return. QBotix disrupts today's cost curve of fixed-tilt, single-axis tracking, and dual-axis tracking with an innovative tracking solution that offers dual-axis tracking at single-axis price. This reduces the levelized cost of energy by 10-20% while providing the added benefit of higher reliability and system intelligence.

Velocomp LLC is a sports technology company based in Boca Raton, Florida, specializing in power measurement tools for cyclists worldwide. Founded in 2006, Velocomp offers a variety of products designed to enhance cycling performance and provide detailed ride analytics. Their product lineup includes the iSport, a wireless cycling computer and power meter; the iPro, which tracks progress and analyzes rides; the iBike POWERHOUSE, a cycling computer that adjusts to exercise goals; and the iAero, which assists in power and wind tunnel measurements. Additionally, Velocomp provides the iDash series, which includes various cycling and fitness computers, as well as protective bicycle cases and mounts for iPhone and iPod touch. The company's products are distributed through dealers across multiple states in the U.S.

Zixi, LLC specializes in providing innovative solutions for the delivery of broadcast-quality HD video over the Internet, Wi-Fi, and mobile networks. Founded in 2006 and headquartered in Waltham, Massachusetts, the company offers the Zixi Video Transport Platform, which serves broadcasters, enterprises, and over-the-top video providers globally. This platform facilitates the seamless transmission of live and on-demand video content while ensuring high quality and efficiency. Zixi's offerings include automated content quality analytics, ZEN Management for channel orchestration, and various applications such as news gathering, sports broadcasting, and virtual events. Additionally, Zixi provides cloud services for live events and video distribution tailored for mobile users and enterprises. Through its technology, Zixi transforms unmanaged connections into reliable networks for video delivery, enabling users to adopt more dynamic and cost-effective broadcasting models. The company maintains a strategic partnership with PeerTV Ltd., enhancing its market reach and service capabilities.